Market leadership EMS is the leading Brazilian pharmaceutical manufacturer with a 19-year market leadership streak and a strong regional manufacturing footprint across multiple facilities, suggesting opportunities for enterprise partnerships, long-term supply contracts, and expanded distribution arrangements.

Genéricos strength Dominant position in generics since 2013 indicates a hill for value-focused portfolio selling, with potential to upsell high-volume generic lines to wholesalers, retailers, and hospital networks seeking cost-effective alternatives.

Global expansion Active international footprint exporting to more than 40 countries and investments in US and European R&D capabilities point to cross-border collaboration opportunities, including co-development, licensing, and strategic partnerships for global product launches.

Innovation drive Strong focus on R&D and modern facilities, including biotechnological programs and disruptive innovation through Brace Pharma and Vero Biotech, creating openings for advanced therapies, contract development and manufacturing (CDMO) partnerships, and pilot programs.

Social and compliance Partnered social initiatives with OMS and a robust compliance-backed innovation footprint can be leveraged to position EMS for government and NGO tenders, public-sector supply deals, and CSR-aligned procurement opportunities with health agencies.